Profile data is unavailable for this security.
About the company
Paradigm Biopharmaceuticals Limited is a late-stage drug development company. The Company is engaged in discovering, developing, and delivering pharmaceutical therapies. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). Pentosan polysulfate sodium is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). It develops PPS under the brand name Zilosul. PPS also inhibits the synthesis of the metalloproteinase, MMP-3 (Troeberg) involved in degrading cartilage. PPS also include treatment of joint function, mobility, and pain in patients with MPS; treating alphavirus-induced arthralgia (such as Ross River virus and Chikungunya); chronic heart failure (HF) and acute respiratory distress syndrome (ARDS).
- Revenue in AUD (TTM)6.52m
- Net income in AUD-58.65m
- Incorporated2014
- Employees--
- LocationParadigm Biopharmaceuticals LtdLevel 15, 500 Collins StMELBOURNE 3000AustraliaAUS
- Phone+61 39629-5566
- Fax+61 39629-5466
- Websitehttps://paradigmbiopharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anteotech Ltd | 514.89k | -8.88m | 58.27m | 40.00 | -- | 9.38 | -- | 113.18 | -0.0039 | -0.0039 | 0.0002 | 0.0021 | 0.0699 | -- | 2.55 | -- | -120.47 | -75.24 | -159.35 | -84.74 | -- | -- | -1,724.74 | -1,444.66 | -- | -- | 0.3055 | -- | 26.85 | 27.93 | 29.82 | -- | 68.39 | -- |
| Neurotech International Ltd | 3.34m | -5.07m | 71.39m | -- | -- | 5.90 | -- | 21.40 | -0.0054 | -0.0054 | 0.0037 | 0.0117 | 0.3807 | 0.00 | 11.59 | -- | -57.86 | -134.56 | -63.92 | -163.66 | 100.00 | -- | -151.98 | -462.38 | 38.81 | -- | 0.00 | -- | 165.98 | 67.39 | 34.94 | -- | -- | -- |
| Percheron Therapeutics Ltd | 615.48k | -11.92m | 76.72m | 8.00 | -- | 7.13 | -- | 124.65 | -0.0135 | -0.0135 | 0.0007 | 0.0104 | 0.045 | -- | 0.2912 | -- | -87.09 | -75.92 | -122.82 | -89.91 | -- | -- | -1,936.57 | -4,028.81 | -- | -1,956.65 | 0.0042 | -- | 59.90 | 56.21 | -4.74 | -- | -- | -- |
| Actinogen Medical Ltd | 291.02k | -13.04m | 80.15m | -- | -- | 3.59 | -- | 275.41 | -0.0061 | -0.0061 | 0.0001 | 0.0072 | 0.0159 | -- | 0.0433 | -- | -71.44 | -48.56 | -78.20 | -51.97 | -- | -- | -4,482.26 | -5,188.44 | -- | -163.10 | 0.0159 | -- | -20.63 | 7.31 | -21.32 | -- | -- | -- |
| Proteomics International LaboratoriesLtd | 1.41m | -6.38m | 85.81m | -- | -- | 9.11 | -- | 60.87 | -0.0507 | -0.0507 | 0.0112 | 0.0719 | 0.1346 | -- | 6.45 | -- | -61.88 | -60.46 | -67.65 | -69.49 | -- | -- | -459.82 | -290.18 | -- | -208.63 | 0.0331 | -- | -4.24 | -1.45 | -3.23 | -- | 60.39 | -- |
| Argenica Therapeutics Ltd | 192.09k | -5.48m | 92.23m | -- | -- | 6.38 | -- | 480.12 | -0.0518 | -0.0518 | 0.0019 | 0.1128 | 0.0148 | -- | 0.7326 | -- | -42.28 | -- | -50.70 | -- | -- | -- | -2,852.56 | -- | -- | -21,829.87 | 0.00 | -- | 214.90 | -- | -13.80 | -- | -- | -- |
| LTR Pharma Ltd | 49.00k | -6.95m | 103.02m | -- | -- | 57.61 | -- | 2,102.42 | -0.0499 | -0.0499 | 0.0004 | 0.0211 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -14,192.84 | -- | -- | -414.02 | 0.00 | -- | -- | -- | -378.00 | -- | -- | -- |
| Paradigm Biopharmaceuticals Ltd | 6.52m | -58.65m | 113.73m | -- | -- | 4.78 | -- | 17.44 | -0.1875 | -0.1875 | 0.0186 | 0.068 | 0.138 | -- | 1.10 | -- | -124.19 | -52.89 | -150.28 | -58.06 | 99.86 | -- | -899.60 | -543.63 | -- | -961.47 | 0.006 | -- | -23.22 | 14.97 | -12.99 | -- | -- | -- |
| Cogstate Ltd | 66.70m | 8.37m | 166.70m | 61.00 | 19.91 | 2.62 | 13.25 | 2.50 | 0.0485 | 0.0485 | 0.3853 | 0.368 | 0.7762 | -- | 4.96 | -- | 9.74 | 8.45 | 12.51 | 12.30 | 55.96 | 53.13 | 12.55 | 10.75 | -- | -- | 0.0162 | 0.00 | 7.36 | 14.72 | 52.75 | -- | -5.00 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Allianz Global Investors GmbHas of 17 May 2024 | 21.31m | 6.09% |
| Allianz Global Investors Asia Pacific Ltd.as of 31 Jul 2024 | 13.91m | 3.97% |
| RBC Global Asset Management (Asia) Ltd.as of 30 Sep 2024 | 10.32m | 2.95% |
| Netwealth Investments Ltd.as of 14 Aug 2024 | 7.23m | 2.07% |
| Pictet Asset Management SAas of 30 Jun 2024 | 2.25m | 0.64% |
| Pictet Asset Management (Singapore) Pte Ltd.as of 30 Jun 2024 | 906.94k | 0.26% |
| DFA Australia Ltd.as of 30 Sep 2024 | 130.42k | 0.04% |
| Dimensional Fund Advisors LPas of 31 Jul 2024 | 119.28k | 0.03% |
| Dimensional Fund Advisors Ltd.as of 31 Aug 2024 | 15.03k | 0.00% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 0.00 | 0.00% |
